EP Patent

EP3461480A1 — Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer

Assigned to Valerio Therapeutics SA · Expires 2019-04-03 · 7y expired

What this patent protects

The present invention relates to the combination of a DNA damage response (DDR) cell cycle checkpoint inhibitor selected from the group consisting of an ATR inhibitor (ATRi) and a CHK1 inhibitor (CHKli) and belinostat for treating cancer.

USPTO Abstract

The present invention relates to the combination of a DNA damage response (DDR) cell cycle checkpoint inhibitor selected from the group consisting of an ATR inhibitor (ATRi) and a CHK1 inhibitor (CHKli) and belinostat for treating cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP3461480A1
Jurisdiction
EP
Classification
—
Expires
2019-04-03
Drug substance claim
No
Drug product claim
No
Assignee
Valerio Therapeutics SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.